The Experts below are selected from a list of 4806 Experts worldwide ranked by ideXlab platform

Yukio Shimono - One of the best experts on this subject based on the ideXlab platform.

  • assessment of microvascular No Reflow pheNomeNon using technetium 99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

  • Assessment of “microvascular No-Reflow pheNomeNon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

Makoto Kondo - One of the best experts on this subject based on the ideXlab platform.

  • assessment of microvascular No Reflow pheNomeNon using technetium 99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

  • Assessment of “microvascular No-Reflow pheNomeNon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

Lei Han - One of the best experts on this subject based on the ideXlab platform.

  • Advances in No-Reflow PheNomeNon
    Advances in Cardiovascular Diseases, 2009
    Co-Authors: Lei Han
    Abstract:

    The No-Reflow pheNomeNon after reperfusion in patients with acute myocardial infarction is an independent predictor of a poor progNosis.In recent years various therapeutic strategies have been used to deal with No-Reflow such as: plaque removal and distal protection devices,vasodilators,anti-platelet agents,improving endothelial function,leukocyte adhesion inhibition,and reperfusion injury reduction.The No-Reflow pheNomeNon,however,has Not been fully resolved.This review is focused on the definition and recent advances on the mechanism of,and the management of,the No-Reflow pheNomeNon.

Daiki Saito - One of the best experts on this subject based on the ideXlab platform.

  • assessment of microvascular No Reflow pheNomeNon using technetium 99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

  • Assessment of “microvascular No-Reflow pheNomeNon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

Akira Nakano - One of the best experts on this subject based on the ideXlab platform.

  • assessment of microvascular No Reflow pheNomeNon using technetium 99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”

  • Assessment of “microvascular No-Reflow pheNomeNon” using technetium-99m macroaggregated albumin scintigraphy in patients with acute myocardial infarction
    Journal of the American College of Cardiology, 1998
    Co-Authors: Makoto Kondo, Akira Nakano, Daiki Saito, Yukio Shimono
    Abstract:

    Abstract Objectives. The aim of this study was the scintigraphic evaluation of clinical No-Reflow pheNomeNon. Background. In patients with acute myocardial infarction, the relationship of the severity of reduction of microvascular Reflow to the ischemia time or to the secondary extension of myocardial necrosis is poorly understood, and we accordingly conducted a scintigraphic evaluation of clinical No-Reflow pheNomeNon. Methods. The group studied consisted of 25 consecutive patients with their first acute myocardial infarction. After recanalization, each patient received intracoronary injections of technetium-99m macroaggregated albumin (MAA). Results. Eight patients (32%) had absent tracer uptake (scintigraphic No-Reflow pheNomeNon). Fourteen patients showed absent or moderately reduced MAA uptake (group 1) and 11 showed slightly reduced or Normal uptake (group 2). The time to recanalization was significantly longer in group 1 than in group 2 (290.4 ± 130.6 min vs. 177.3 ± 93.5 min; p = 0.0238). In chronic phase, the thallium-201 (Tl-201) defect score index was significantly larger (p Conclusions. These findings suggest that scintigraphic No-Reflow pheNomeNon occurs in a subgroup of patients without angiographic No-Reflow pheNomeNon, that the myocardial damage depends on the severity of microvascular damage and that prolonged ischemia time may increase the likelihood of “microvascular No-Reflow pheNomeNon.”